Navigation Links
Cequent to Provide Details at BIOCOM About Planned Launch of its Clinical Program - 3 p.m., Tuesday, October 27
Date:10/13/2009

CAMBRIDGE, Mass., Oct. 13 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Chief Executive Officer, Peter Parker, will provide details on Cequent's planned launch of its clinical program and highlight strategy and development goals in a company update scheduled for 3 p.m. on Tuesday, October 27, 2009, at the 2009 BIOCOM Investor Conference. The company has initiated a Series B round of financing; it is seeking to raise $15 million to take the company through Phase II clinical trials with its lead drug candidate.

Cequent is using the company's proprietary TransKingdom RNA interference (tkRNAi) technology to develop RNAi-based therapeutics - a new class of drugs designed to work by effectively deactivating the specific gene or genes implicated in the progression of a disease. The company has made considerable progress with its programs targeting polyposis and inflammatory bowel disease (IBD), demonstrating through in vivo testing and studies with non-human primates that its tkRNAi technology can silence target genes successfully. It expects to file its first IND (investigational new drug) application with the U.S. Food and Drug Administration for an orally administered tkRNAi drug targeting the primary oncogene in FAP (familial adenomatous polyposis) before the end of the quarter. FAP is a rare inherited gastrointestinal disease that causes hundreds to thousands of precancerous polyps to form in the colon, leading to colon cancer.

Cequent completed a $15 million Series A financing in June of 2007. Investors included Ampersand Ventures, Pappas Ventures, Yasuda, and the Novartis Option Fund.

2009 BIOCOM Investor Conference

The fourth annual BIOCOM Investor Conference takes place October 26 - 27, 2009, at the Hyatt Regency La Jolla, California. For more informat
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
3. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
4. Cequent Names Ted Hibben Chief Business Officer
5. Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases
6. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
7. CardioDynamics Provides 2007 Shareholder Meeting Update
8. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
9. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
10. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
11. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... ... initiative to create the next generation of fertilizers and production technologies, with initial financial ... ... -- IFDC is launching the Virtual Fertilizer Research Center (VFRC), a global ...
... , ... ... ... , ...
... ... ... ... ...
Cached Biology Technology:IFDC Launches Virtual Fertilizer Research Center 2IFDC Launches Virtual Fertilizer Research Center 3IFDC Launches Virtual Fertilizer Research Center 4IFDC Launches Virtual Fertilizer Research Center 5Icahn Nominates 4 to Genzyme Slate 2Icahn Nominates 4 to Genzyme Slate 3Icahn Nominates 4 to Genzyme Slate 4Icahn Nominates 4 to Genzyme Slate 5Icahn Nominates 4 to Genzyme Slate 6Icahn Nominates 4 to Genzyme Slate 7Icahn Nominates 4 to Genzyme Slate 8Icahn Nominates 4 to Genzyme Slate 9Icahn Nominates 4 to Genzyme Slate 10Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 2Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 3Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 4Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 5Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 6
(Date:4/16/2014)... U.S. and beyond will convene in Lincoln, Nebraska, USA, ... existing science, and explore the unique geologic and historic ... applied geology, paleontology, and mid-continent geology. Events include a ... Kirk Johnson, Sant Director of the Smithsonian National Museum ... by the University of Nebraska-Lincoln. Lincoln is located near ...
(Date:4/16/2014)... Our ability to store memories improves during childhood, ... its connections with prefrontal and parietal cortices. New ... brain regions develop at this crucial time. Eventually, ... emerge in the transition into and during adolescence ... , Located deep in the middle of the ...
(Date:4/16/2014)... Martin Prechtl, Leo Heim and their colleagues at the ... new method of generating hydrogen using water and formaldehyde. ... interest when it comes to fuel cell technologies. The ... production using water and formaldehyde", have recently been published ... other applications, the new approach can be used to ...
Breaking Biology News(10 mins):Walking with mammoths and exploring mid-continental geology 2Walking with mammoths and exploring mid-continental geology 3Walking with mammoths and exploring mid-continental geology 4How kids' brain structures grow as memory develops 2
... the diaphragm muscles has received approval from the Food and ... Sclerosis (ALS), also known as Lou Gehrig,s disease. The ... patients breathe longer without the aid of a ventilator. ... Medical Center who helped develop and test DPS and who ...
... in the October 2011 print issue of The FASEB ... what kicks off the process that causes varicose veins. In ... binds to DNA to control gene function (called "transcription factor ... of proteins that significantly affect the development of varicose veins. ...
... work of a team of scientists at Cold Spring Harbor ... way to overcome one of the major technical obstacles preventing ... addressed successfully by novel drugs. The target is ... long known to be an important player in the signaling ...
Cached Biology News:Diaphragm pacing system receives FDA approval for use with ALS patients 2Scientists discover the proteins that control development of varicose veins 2Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity 2Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity 3Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity 4
... Gene expression profiling allows a high-throuput screening ... naturally occuring or artifitially induced changes in ... that system can be detected, studied, classified ... broad range of genes at a glance. ...
... SYBR Green II RNA gel stain ... stain that has bright fluorescence when bound ... making it ideal for use with either ... or standard UV transilluminators. A 500 µL ...
Rabbit polyclonal to Esa1 ( Abpromise for all tested applications)....
... RNA gel stain is a sensitive nucleic ... bound to RNA and low background in gels, ... or polyacrylamide gels using laser scanners or standard ... 500 µL unit size (S-7564) and a special ...
Biology Products: